2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1685 Clinical and genomic predictors of response and survival in secondary AML treated with CPX-351: A real-world analysis

Sarvarinder Kaur Gill, MD, Jamie Koprivnikar, MD2, James K. McCloskey, MD3
1 John Theurer Cancer Canter at Hackensack University Medical Center, Hackensack, New Jersey, United States
2 John Theurer Cancer Canter at Hackensack University Medical Center, Hackensack, New Jersey, United States
3 John Theurer Cancer Canter at Hackensack University Medical Center, Hackensack, New Jersey, United States

Background: CPX-351, a liposomal encapsulation of cytarabine and daunorubicin at a synergistic 5:1 molar ratio, has demonstrated improved outcomes compared to standard 7+3 induction in older adults with therapy-related acute myeloid leukemia (t-AML) and AML with myelodysplasia-related changes (AML-MR). However, in real-world clinical practice, patient outcomes remain highly heterogeneous. The precise clinical and molecular determinants that dictate response and long-term survival outside of the clinical trial setting are incompletely defined. This study aimed to comprehensively define the clinical and genomic predictors of response and survival in a real-world cohort of patients with newly diagnosed secondary AML treated with CPX-351.

Methods: We conducted a retrospective, single-center study of 112 adults with newly diagnosed secondary AML who received induction therapy with CPX-351 between September 2017 and August 2024. Baseline genomic profiling was performed using targeted next-generation sequencing (NGS). Treatment response was assessed per European LeukemiaNet (ELN) 2022 criteria. Measurable residual disease (MRD) was assessed by multiparameter flow cytometry (sensitivity <10^-5). Survival distributions were estimated by the Kaplan-Meier method and compared using the log-rank test. Hazard ratios (HRs) were estimated using Cox proportional hazards regression.

Results: The median age was 63 years (range, 21–77), and 51% (57/112) were male. Per ELN 2022 criteria, 8% had favorable, 17% intermediate, and 75% adverse-risk disease. The most frequent mutations were TP53 (31%), DNMT3A (26%), ASXL1 (19%), NRAS (13%), and RUNX1 (13%). The overall response rate (CR/CRi) was 64% (72/112). Among responders with available data, 46% (30/65) achieved MRD negativity. After a median follow-up of 33.3 months, the median overall survival (OS) and event-free survival (EFS) were 11.96 (95% CI, 9.12–21.45) and 4.86 months (95% CI, 3.61–8.84), respectively, with 1- and 2-year OS rates of 49.0% and 33.7%. Median OS varied significantly by ELN risk: not reached for favorable, 72.83 months for intermediate, and 9.76 months for adverse risk (P=0.007). Allogeneic hematopoietic cell transplantation (allo-HCT) was performed in 44% of patients and was associated with markedly improved survival (median OS, 72.87 vs 6.11 months). On univariable analysis, adverse karyotype and TP53 mutations were associated with inferior OS (HR 4.59, P=0.034; and HR 2.69, P<0.001, respectively). TP53 mutation remained independently associated with inferior OS on multivariable analysis (HR 2.11, P=0.005). Conversely, DNMT3A mutations, achievement of CR/CRi, and allo-HCT were associated with improved OS on univariable analysis (HR 0.49, P=0.022; HR 0.48, P=0.003; and HR 0.15, P<0.001, respectively). DNMT3A mutations and allo-HCT retained significance on multivariable analysis (P=0.011 and P<0.001, respectively). Secondary-type mutations showed a trend toward improved survival compared with de novo AML. MRD-negative patients had a median OS of 19.02 vs 10.74 months for MRD-positive patients, though this did not reach statistical significance (P=0.193).

Conclusions: In this real-world cohort, response rates and survival outcomes with CPX-351 were consistent with pivotal clinical trial data, confirming its efficacy in secondary AML. Long-term survival was primarily driven by the ability to bridge to allo-HCT and the patient's underlying molecular risk profile. TP53 mutations identify a high-risk subgroup with particularly poor outcomes despite CPX-351 therapy, representing a critical unmet need. Notably, DNMT3A mutations emerged as an independent predictor of improved survival. These findings highlight the curative potential of allo-HCT and strongly support the early integration of comprehensive genomic profiling to guide risk-adapted therapeutic strategies in secondary AML. Novel strategies are urgently needed for TP53-mutated AML and patients unable to proceed to transplantation.

Sarvarinder Kaur Gill, MD: No relevant conflicts of interest to declare.